Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems

NCT00382837 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00382837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00382837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Withdrawn
Start date
January 31, 2007
Completion date
Not reported
Enrollment
0 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus